title: Prospect of rindopepimut in the treatment of glioblastoma.
abstract: Rindopepimut (CDX-110) is a peptide vaccine that targets epidermal growth factor receptor variant III (EGFRvIII), a tumor-specific epitope expressed in the most common and lethal primary malignant neoplasm of the brain - glioblastoma (GBM). Areas covered: The EGFRvIII mutation introduces an 801 base pair in-frame deletion of the extracellular domain of the transmembrane tyrosine kinase, resulting in constitutive kinase activity, amplification of cell growth, and inhibition of apoptosis. Rindopepimut contains a 14mer amino acid peptide spanning the EGFRvIII mutation site that is conjugated to keyhole limpet hemocyanin (KLH). The EGFRvIII neoantigen is exclusively present on GBM cells, providing rindopepimut tumor-specific activity. The authors review rindopepimut's clinical efficacy, administration, safety, and prospects in the treatment of GBM. Expert opinion: Rindopepimut showed clinical benefit and significant efficacy in phase II clinical trials, including as part of a multi-immunotherapy approach. A phase III clinical trial was terminated early, however, as it was deemed likely the study would fail to meet its primary endpoint. Longer term and sub-group analyses will be necessary to better understand rindopepimut's future role in GBM therapy.
authors.affiliation: a Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery , Duke University Medical Center , Durham , NC , USA.|b The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center , Durham , NC , USA.
authors.forename: Aladine A
authors.initials: AA
authors.lastname: Elsamadicy
authors.affiliation: a Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery , Duke University Medical Center , Durham , NC , USA.|b The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center , Durham , NC , USA.|c Department of Pathology , Duke University Medical Center , Durham , NC , USA.
authors.forename: Pakawat
authors.initials: P
authors.lastname: Chongsathidkiet
authors.affiliation: d Department of Neurosurgery , Washington University School of Medicine in St. Louis , St. Louis , MO , USA.
authors.forename: Rupen
authors.initials: R
authors.lastname: Desai
authors.affiliation: a Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery , Duke University Medical Center , Durham , NC , USA.|b The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center , Durham , NC , USA.|c Department of Pathology , Duke University Medical Center , Durham , NC , USA.
authors.forename: Karolina
authors.initials: K
authors.lastname: Woroniecka
authors.affiliation: a Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery , Duke University Medical Center , Durham , NC , USA.|b The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center , Durham , NC , USA.
authors.forename: S Harrison
authors.initials: SH
authors.lastname: Farber
authors.affiliation: a Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery , Duke University Medical Center , Durham , NC , USA.|b The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center , Durham , NC , USA.|c Department of Pathology , Duke University Medical Center , Durham , NC , USA.
authors.forename: Peter E
authors.initials: PE
authors.lastname: Fecci
authors.affiliation: a Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery , Duke University Medical Center , Durham , NC , USA.|b The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center , Durham , NC , USA.|c Department of Pathology , Duke University Medical Center , Durham , NC , USA.
authors.forename: John H
authors.initials: JH
authors.lastname: Sampson
mesh_terms: D000818:Animals; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D019496:Cancer Vaccines / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005909:Glioblastoma / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D022223:Vaccines, Subunit / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D019496:Cancer Vaccines; D022223:Vaccines, Subunit; C410723:epidermal growth factor receptor VIII; D066246:ErbB Receptors; C558237:rindopepimut
keywords: EGFRvIII; Glioblastoma; clinical trials; immunotherapy; peptide vaccine; rindopepimut